Prognostic Role of AI-Echo
ConditionAtrial Cardiomyopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorUniversity of Calabria
About this trial
Left atrial cardiomyopathy (LACM) is frequently underdiagnosed but plays a key role in increasing the risk of atrial fibrillation (AF) and thromboembolic events. While atrial strain is a validated marker of LACM, its measurement with conventional echocardiography can be time-consuming and less feasible in acute settings. The use of AI-assisted echocardiography (AI-echo) may help streamline image acquisition and analysis, offering faster and potentially more accurate assessment.
This study aims to compare the time required for atrial strain analysis using AI-echo versus standard methods. It also explores how changes in strain parameters (LASr, LASct, LAScd) relate to the onset of AF and in-hospital adverse outcomes, adjusting for comorbidities and conventional echo variables.
Main endpoints include time reduction with AI-echo and the association between strain changes and AF, complications, or mortality during hospitalization.
Eligibility criteria
Qualifiers
Age between 18 and 85 years.
Hospitalization in CCU for acute cardiac pathology (e.g. acute coronary syndrome, acute or exacerbated heart failure, malignant arrhythmias, etc.).
Ability to provide written informed consent.
Disqualifiers
Severe hemodynamic instability, history to contraindicate the execution of the echocardiographic examination.
Severely inadequate echocardiographic window that precludes atrial or ventricular morpho-functional assessment.
Inability to continue the study for clinical reasons, logistics or patient refusal.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov